-
公开(公告)号：US20220204971A1
公开(公告)日：2022-06-30
申请号：US17263099
申请日：2019-07-25
Inventor： Maciej T. Nogalski , Alexander Solovyov , Thomas Shenk , Benjamin D. Greenbaum
IPC: C12N15/113
Abstract: The present invention relates to compositions comprising isolated, single stranded RNA molecules and pharmaceutically acceptable carriers suitable for injection. The present invention relates to methods for stimulating an immune response and treating tumors. The present invention further relates to kits comprising a cancer vaccine and compositions of the present invention for use as an adjuvant to cancer vaccines.
-
公开(公告)号：US20210318312A1
公开(公告)日：2021-10-14
申请号：US16991429
申请日：2020-08-12
Applicant: THE TRUSTEES OF PRINCETON UNIVERSITY
Inventor： Thomas Shenk , Todd M. Greco , Ileana M. Cristea , Rommel A. Mathias , Adam Oberstein
IPC: G01N33/573 , C12Q1/34
Abstract: The present application demonstrates that sirtuin 4 (SIRT4) acts as a cellular lipoamidase that negatively regulates pyruvate dehydrogenase complex (PDHC) activity through hydrolysis of its lipoamide cofactors.
-
公开(公告)号：US10788492B2
公开(公告)日：2020-09-29
申请号：US15106932
申请日：2015-01-15
Applicant: THE TRUSTEES OF PRINCETON UNIVERSITY
Inventor： Thomas Shenk , Todd M. Greco , Ileana M. Cristea , Rommel A. Mathias , Adam Oberstein
IPC: C12Q1/34 , G01N33/573
Abstract: The present application demonstrates that sirtuin 4 (SIRT4) acts as a cellular lipoamidase that negatively regulates pyruvate dehydrogenase complex (PDHC) activity through hydrolysis of its lipoamide cofactors.
-
公开(公告)号：US20190218524A1
公开(公告)日：2019-07-18
申请号：US16366278
申请日：2019-03-27
Applicant: The Trustees of Princeton University
Inventor： Emre Koyuncu , Ileana M. Cristea , Thomas Shenk
CPC classification number: C12N7/00 , C12N5/0018 , C12N2500/36 , C12N2501/999 , C12N2710/16151 , C12N2710/16751
Abstract: A method is provided to improve virus production is an infected host cell by culturing the infected cell in an effective amount of alpha-ketoglutarate.
-
公开(公告)号：US20180346885A1
公开(公告)日：2018-12-06
申请号：US16054590
申请日：2018-08-03
Applicant: The Trustees of Princeton University
Inventor： Thomas Shenk , Nicole Gudleski O'Regan , Todd M. Greco , Ileana M. Cristea
IPC: C12N7/00
CPC classification number: C12N7/00 , A61K39/25 , C12N2710/16151 , C12Q1/705
Abstract: A method for enhancing infectivity of HCMV virus particles is provided.
-
Patent Agency Ranking
公开(公告)号：US09757407B2
公开(公告)日：2017-09-12
申请号：US14977424
申请日：2015-12-21
Applicant: The Trustees of Princeton University
Inventor： Josh Munger , Bryson Bennett , Thomas Shenk , Joshua Rabinowitz
IPC: A61K31/335 , A61K31/7076 , A61K31/381 , A61K31/336 , A61K31/341 , A61K31/365 , A61K31/122 , A61K31/15 , A61K31/194 , A61K31/337 , A61K31/357 , A61K31/403 , A61K31/4545 , A61K31/53 , A61K31/5377 , A61K31/351 , A61K31/675 , A61K31/706 , A61K31/44 , A61K31/22 , A61K31/221 , A61K31/522 , A61K31/52 , A61K31/405
CPC classification number: A61K31/7076 , A61K31/122 , A61K31/15 , A61K31/194 , A61K31/22 , A61K31/221 , A61K31/336 , A61K31/337 , A61K31/341 , A61K31/351 , A61K31/357 , A61K31/365 , A61K31/381 , A61K31/403 , A61K31/405 , A61K31/44 , A61K31/4545 , A61K31/52 , A61K31/522 , A61K31/53 , A61K31/5377 , A61K31/675 , A61K31/706 , Y02A50/463 , A61K2300/00
Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.
-
17.发明申请TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS 审中-公开通过调节宿主细胞代谢途径治疗病毒感染公开(公告)号：US20160346309A1
公开(公告)日：2016-12-01
申请号：US14977424
申请日：2015-12-21
Applicant: The Trustees of Princeton University
Inventor： Josh Munger , Bryson Bennett , Thomas Shenk , Joshua Rabinowitz
IPC: A61K31/7076 , A61K31/336 , A61K31/341 , A61K31/194 , A61K31/381 , A61K31/53 , A61K31/403 , A61K31/4545 , A61K31/5377 , A61K31/357 , A61K31/15 , A61K31/337 , A61K31/365 , A61K31/122
CPC classification number: A61K31/7076 , A61K31/122 , A61K31/15 , A61K31/194 , A61K31/22 , A61K31/221 , A61K31/336 , A61K31/337 , A61K31/341 , A61K31/351 , A61K31/357 , A61K31/365 , A61K31/381 , A61K31/403 , A61K31/405 , A61K31/44 , A61K31/4545 , A61K31/52 , A61K31/522 , A61K31/53 , A61K31/5377 , A61K31/675 , A61K31/706 , Y02A50/463 , A61K2300/00
Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.
Abstract translation: 描述了响应于病毒感染发生的某些代谢物浓度和通量的变化。 所选代谢途径中的宿主细胞酶被选为干预的目标; 即恢复代谢通量以不利于病毒复制，或进一步破坏导致病毒感染细胞（但不是未感染细胞）“自杀”的代谢通量，以限制病毒传播。 虽然可以选择相关代谢途径中的任何酶，但在这些代谢途径的关键控制点的关键酶优选作为候选抗病毒药物靶标。 这些酶的抑制剂用于逆转或重定向病毒感染的作用。 使用体外和宿主细胞的筛选测定以及动物模型测试候选药物的抗病毒活性。 然后使用动物模型来测试候选化合物在预防和治疗病毒感染中的功效。 证明酶抑制剂的抗病毒活性。
-
公开(公告)号：US11008551B2
公开(公告)日：2021-05-18
申请号：US16054590
申请日：2018-08-03
Applicant: The Trustees of Princeton University
Inventor： Thomas Shenk , Nicole Gudleski O'Regan , Todd M. Greco , Ileana M. Cristea
Abstract: A method for enhancing infectivity of HCMV virus particles is provided.
-
公开(公告)号：US20160130565A1
公开(公告)日：2016-05-12
申请号：US14935061
申请日：2015-11-06
Applicant: The Trustees of Princeton University
Inventor： Thomas Shenk , Emre Koyuncu , Joshua D. Rabinowitz
IPC: C12N7/00
CPC classification number: C12N7/00 , C12N2710/16151 , C12N2710/16751
Abstract: A method for improving virus production in a host cell infected with the virus is provided.
Abstract translation: 提供了用于改善感染病毒的宿主细胞中病毒产生的方法。
-
公开(公告)号：US20150335657A1
公开(公告)日：2015-11-26
申请号：US14703371
申请日：2015-05-04
Applicant: The Trustees of Princeton University
Inventor： Thomas Shenk , Emre Koyuncu , Hahn Kim , Ileana Cristea , David MacMillan
IPC: A61K31/554 , A61K31/519 , A61K45/06 , A61K31/502 , A61K31/4709 , A61K31/4155 , A61K31/444 , A61K31/4439 , A61K31/42 , A61K31/4178 , A61K31/4164 , A61K31/553 , A61K31/4412 , A61K31/496 , A61K31/4015 , A61K31/415 , A61K31/4725 , A61K31/501 , A61K31/47
CPC classification number: A61K31/554 , A61K31/4015 , A61K31/4045 , A61K31/415 , A61K31/4155 , A61K31/4164 , A61K31/4178 , A61K31/42 , A61K31/44 , A61K31/4412 , A61K31/4439 , A61K31/444 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/501 , A61K31/502 , A61K31/519 , A61K31/553 , A61K45/06 , Y02A50/467
Abstract: This document relates to compounds useful for modulating sirtuin enzymes. For example, the compounds provided herein are useful as broad spectrum antiviral agents. In addition, the compounds provided herein may be used in the treatment of other disorders associated with sirtuin enzymes, such as diseases related to aging and stress, blood clotting disorders, cancer, cardiovascular diseases, diabetes, inflammation, neurodegenerative diseases, and obesity.
Abstract translation: 本文件涉及可用于调节沉默调节蛋白酶的化合物。 例如，本文提供的化合物可用作广谱抗病毒剂。 此外，本文提供的化合物可用于治疗与沉默调节蛋白酶相关的其它疾病，例如与衰老和压力相关的疾病，凝血障碍，癌症，心血管疾病，糖尿病，炎症，神经变性疾病和肥胖症。
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.037 seconds)
